Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21574822 | 0.90 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 | |
| SCHEMBL6508653 | 0.89 | TSHR (0.67) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 | |
| SCHEMBL13259140 | 0.82 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 | |
| SCHEMBL21574804 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAMMP2MMP12 | |
| SCHEMBL25042284 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6780349 | 0.81 | AGXT (0.44) | ALDH1A1SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL22764713 | 0.80 | TSHR (0.54) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 | |
| SCHEMBL22766620 | 0.80 | TSHR (0.54) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 | |
| SCHEMBL20120353 | 0.78 | CA1 (0.47) | ALDH1A1SMN1; SMN2POLBCA1CA2 | |
| SCHEMBL7772144 | 0.78 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRLMNAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292780-B2 | Process for preparing cyclic carbonates | BASF SE (DE) | 2022-04-05 | — | — | US | disclosed |
| EP-3668849-B1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3668849-B1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20200369640-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20200369640-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2020-11-26 | — | — | US | disclosed |
| EP-3668849-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034648-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034648-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | BASF SE (DE) | 2019-02-21 | — | — | WO | disclosed |
| EP-2822557-B1 | PREPARATION AND USE OF BICYCLIC HIMBACINE DERIVATIVES AS PAR-RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1497273-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-06-09 | — | — | EP | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001046156-A1 | BUTYNE DIOL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-06-28 | — | — | WO | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0318214-B1 | Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof | SCHERING CORP (US) | 1994-12-14 | — | — | EP | disclosed |
| US-5039676-A | Fungicide, antiallergens | SCHERING CORPORATION (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0386143-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004829-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1989-06-01 | — | — | WO | disclosed |
| EP-0318214-A1 | Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof | SCHERING CORPORATION (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292780-B2 | Process for preparing cyclic carbonates | ADH1C, EMC1, RFC1 | ALDH1A1 168/4885SMN1; SMN2 2711/4885TSHR 2167/4885 |
| US-20200369640-A1 | PROCESS FOR PREPARING CYCLIC CARBONATES | ADH1C, EMC1, RFC1 | ALDH1A1 168/4885SMN1; SMN2 2711/4885TSHR 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.